Terek Mustafa Cosan, Akman Levent, Hursitoglu Behiye Seda, Sanli Ulus Ali, Ozsaran Zeynep, Tekindal Mustafa Agah, Dikmen Yilmaz, Zekioglu Osman, Ozsaran Ahmet Aydin
Department of Obstetrics and Gynecology, Ege University Medical School, Izmir, Turkey.
J Cancer Res Ther. 2016 Jan-Mar;12(1):309-13. doi: 10.4103/0973-1482.148698.
Uterine sarcomas are rare, malignant, gynecological tumors and show diverse histopathological features. Therefore, there is no consensus on risk factors for poor outcome and optimal treatment. The aim of this retrospective analysis is to report the clinical outcome of patients with uterine sarcoma treated at a single center.
The data was obtained regarding the patient's demographic characteristics, pathological results, treatments given, survival, and complications of all uterine sarcoma patients treated in a single center between the years 2000 and 2012. The 80.month overall survival. (OS) was determined with respect to prognostic factors including age, stage of disease, histopathological type, and adjuvant treatment.
A total of 57 case records are retrieved for this retrospective analysis. The mean age of the patients is 62.5 ± 11.2 years. International Federation of Gynecology and Obstetrics (FIGO) stage distribution is stage I: 29; stage II: 13; stage III: 9; stage IV: 6. Fifty-seven patients underwent surgery, 33 received postoperative radiotherapy (PORT), and 32 received chemotherapy. Median follow-up period was 25 months (range 2-85 months). The 80-month OS for the entire group of patients was 36.7%. The significant prognostic factors for survival are age under 50 years, stage of disease, and adjuvant chemotherapy.
Although limited by small sample size and retrospective nature, age under 50 years, stage of disease, and adjuvant chemotherapy are significant prognostic factors for survival for uterine sarcomas.
子宫肉瘤是罕见的妇科恶性肿瘤，具有多样的组织病理学特征。因此，对于预后不良的危险因素和最佳治疗方法尚无共识。本回顾性分析的目的是报告在单一中心接受治疗的子宫肉瘤患者的临床结局。
获取了2000年至2012年期间在单一中心接受治疗的所有子宫肉瘤患者的人口统计学特征、病理结果、所接受的治疗、生存情况及并发症等数据。根据年龄、疾病分期、组织病理学类型和辅助治疗等预后因素确定80个月总生存率（OS）。
本次回顾性分析共检索到57例病例记录。患者的平均年龄为62.5±11.2岁。国际妇产科联盟（FIGO）分期分布为：I期29例；II期13例；III期9例；IV期6例。57例患者接受了手术，33例接受了术后放疗（PORT），32例接受了化疗。中位随访期为25个月（范围2 - 85个月）。整个患者组的80个月OS为36.7%。生存的显著预后因素为年龄小于50岁、疾病分期和辅助化疗。
尽管受样本量小和回顾性研究性质的限制，但年龄小于50岁、疾病分期和辅助化疗是子宫肉瘤生存的显著预后因素。
